research Case Series and Literature Review on Tofacitinib for Treating Severe Alopecia Areata
Tofacitinib is effective and safe for treating severe alopecia areata.
Search
for
Sort by
Research
420-450 / 1000+ results 
research Retrospective Analysis of Oral Tofacitinib Treatment for Alopecia Areata at a Tertiary Care Hospital in Saudi Arabia
Oral tofacitinib effectively treats alopecia areata long-term with manageable side effects.
research Mechanical Fractionation of Adipose Tissue—A Scoping Review of Procedures to Obtain Stromal Vascular Fraction
tSVF is effective for treating inflammation-related conditions, with centrifugation being the best method for isolation.
research A fixed-dose combination of finasteride and tadalafil (Entadfi) for BPH.
Entadfi, a mix of finasteride and tadalafil, is used for BPH.
research Anticoagulant-free preparation of autologous platelet-rich plasma (PRP) / fluid platelet-rich fibrin (f-PRF): a pre-clinical comparative performance study
Exprecell™ is as effective as traditional methods but produces more f-PRF and is simpler to use.
research 544 Alopecia areata lesions show significant changes in immune and keratin biomarkers that correlate with clinical improvement with oral Janus kinase inhibitors PF-06651600 (JAK3) and PF-06700841 (TYK2/JAK1)
Oral JAK inhibitors improved alopecia areata by modulating immune responses and boosting hair growth.
research Efficacy and safety of autologous adipose-derived stromal vascular fraction enriched with platelet-rich plasma in flap repair of transsphincteric cryptoglandular fistulas
Using SVF enriched with PRP in surgery for certain fistulas is effective and safe.
research Efficacy and safety of tofacitinib in patients with alopecia areata
Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
research First drug for severe alopecia recommended by NICE could benefit 14,000 patients
Ritlecitinib can help about 14,000 people with severe hair loss.
research A systematic review of tumor necrosis factor-α blockers, anti-interleukins, and small molecule inhibitors for dissecting cellulitis of the scalp treatment
TNF-α blockers and IL inhibitors improve symptoms in most patients with severe scalp condition, but more research is needed.
research Oral Tofacitinib for the Management of Moderate to Severe Alopecia Areata in Children and Adolescents: A Retrospective Study of 36 Patients
Tofacitinib helps hair regrow in some kids with severe alopecia areata, but more research is needed on long-term effects.
research Enhanced Insights into Frontal Fibrosing Alopecia: Advancements in Pathogenesis Understanding and Management Strategies
Frontal Fibrosing Alopecia needs better diagnostics and treatments, with dutasteride showing promise.
research A Case of Alopecia Totalis with Lichen Planus Hypertrophicus Responded Excellently to Oral Tofacitinib-An Observation
Tofacitinib effectively improved hair regrowth and skin condition in a woman with alopecia totalis and lichen planus hypertrophicus.
research Betulinic acid exerts anti‐hepatitis C virus activity via the suppression of NF ‐κB‐ and MAPK ‐ERK 1/2‐mediated COX ‐2 expression
Betulinic acid can help treat hepatitis C by stopping virus replication.
research Impact of Combined Baricitinib and FTI Treatment on Adipogenesis in Hutchinson–Gilford Progeria Syndrome and Other Lipodystrophic Laminopathies
Baricitinib and its combination with lonafarnib improve fat cell formation in certain genetic disorders.
research Use of intramuscular triamcinolone acetonide in intermediate responders to janus kinase inhibition for alopecia areata: Case report
IMTA can help regrow hair in severe alopecia areata when JAK inhibitors don't work well.
research Role of Platelet Rich Fibrin (PRF) in Treatment of Post Acne Scars: Review Article
Platelet Rich Fibrin improves healing and reduces acne scars by slowly releasing growth factors.
research La FDA aprueba Litfulo® (ritlecitinib) para el tratamiento de la alopecia areata grave en adolescentes y adultos
The FDA approved Litfulo® for treating severe alopecia areata in people aged 12 and older.
research FORMULATION AND EVALUATION OF A TOPICAL GEL CONTAINING MINOXIDIL AND TOFACITINIB CITRATE FOR ALOPECIA AREATA
The formulated gel is a promising treatment for alopecia areata.
research Keratinocyte-derived follistatin regulates epidermal homeostasis and wound repair
Activin activation in skin cells speeds up wound healing without affecting scar quality.
research Intraoperative floppy iris syndrome
Certain eye surgery complications can be managed effectively, especially in patients who have used specific prostate medications.
research Angiogenesis: a Dynamic Balance of Stimulators and Inhibitors
Angiogenesis can be controlled by balancing stimulators like VPF/VEGF and inhibitors like TSP.
research Targeted Inactivation of Gh/Tissue Transglutaminase II
Tgm2 helps stabilize dying cells and aids fibroblast attachment to the extracellular matrix.
research Efeito terapêutico da toxina botulínica A em foliculite dissecante
Botulinum toxin A helped a patient recover from dissecting folliculitis when antibiotics failed.
research 546 Gene expression signatures and ALADIN score correlates with response of alopecia areata patients to treatment with JAK inhibitors
The ALADIN score can predict how well patients with alopecia areata will respond to JAK inhibitor treatments.
research Rivaroxaban-induced hair loss
Rivaroxaban may cause hair loss.
research Experience with oral tofacitinib in severe alopecia areata with different clinical responses
Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
research Treatment with injectable platelet-rich fibrin in a rat model of melasma
Injectable platelet-rich fibrin can safely and effectively treat melasma.
research Platelet-rich plasma combined with intralesional triamcinolone acetonide for the treatment of alopecia areata: A case report
Mixing platelet-rich plasma with triamcinolone acetonide can potentially improve hair regrowth in alopecia areata patients.
research Moving Beyond Boundaries: Utilization of Longitudinal Exposure–Response Model for Bounded Outcome Score to Inform Decision Making in the Accelerated Drug Development Paradigm
A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.